ezh2 inhibition therapeutic strategy lymphoma ezh2-activating mutations 
eukaryotes post-translational modification histones critical regulation chromatin structure gene expression ezh2 catalytic subunit polycomb repressive complex prc2 involved repressing gene expression methylation histone h3 lysine h3k27 ezh2 overexpression implicated tumorigenesis correlates poor prognosis several tumour types- additionally somatic heterozygous mutations y641 a677 residues within catalytic set domain ezh2 occur diffuse large b-cell lymphoma dlbcl follicular lymphoma- y641 residue frequently mutated residue % germinal centre b-cell dlbcl follicular lymphoma harbouring mutations site lymphomas increased h3k27 tri-methylation h3k27me3 owing altered substrate preferences mutant enzymes- however unknown whether specific direct inhibition ezh2 methyltransferase activity will effective treating ezh2 mutant lymphomas demonstrate gsk126 potent highly selective s-adenosyl-methionine-competitive small-molecule inhibitor ezh2 methyltransferase activity decreases global h3k27me3 levels reactivates silenced prc2 target genes gsk126 effectively inhibits proliferation ezh2 mutant dlbcl cell lines markedly inhibits growth ezh2 mutant dlbcl xenografts mice together data demonstrate pharmacological inhibition ezh2 activity may provide promising treatment ezh2 mutant lymphoma 
